Navigation Links
Novo Nordisk Intends to Appeal Adverse Ruling in Prandin® (repaglinide) Patent Case
Date:1/19/2011

PRINCETON, N.J., Jan. 19, 2011 /PRNewswire/ -- Today, Novo Nordisk announced that Judge Avern Cohn of the US District Court for the Eastern District of Michigan issued an adverse ruling in a patent litigation case regarding Novo Nordisk's US Patent No. 6,677,358. The district court ruled that the patent, which covers the combination use of repaglinide and metformin for the treatment of type 2 diabetes, is invalid and unenforceable. Novo Nordisk markets repaglinide under the trade name Prandin® and a fixed dose repaglinide/metformin tablet under the trade name PrandiMet®. The district court ruling has the potential to facilitate launch of a generic repaglinide. At present, it is unclear whether or when a generic version of Prandin® or PrandiMet® will be available in the U.S. market. Novo Nordisk intends to appeal this ruling and is evaluating its best options for doing so.

(Logo: http://photos.prnewswire.com/prnh/20020404/NVOLOGO)

"We are disappointed with today's ruling. We believe that it is contrary to the evidence and we intend to appeal the ruling," says Jesper Brandgaard, executive vice president and chief financial officer of Novo Nordisk.

For the first nine months of 2010, US sales of Prandin® and PrandiMet® amounted to USD 134 million.

Novo Nordisk is a global healthcare company with 87 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs approximately 30,100 employees in 76 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on NASDAQ OMX Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com.


'/>"/>
SOURCE Novo Nordisk
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Reportlinker Adds Novo Nordisk A/S: PharmaVitae Profile
2. Novo Nordisk A/S and Emisphere Technologies, Inc. Announce License Agreement to Develop Oral Formulation of Insulin for Diabetes
3. Novo Nordisk and Chip Ganassi Racing Team Up for 2011 IZOD IndyCar Series
4. Novo Nordisk and Entertainment Industries Council Work Together to Improve Public Education and Awareness about Diabetes Epidemic
5. Novo Nordisk to Invest $73m in Expansion of U.S. Manufacturing Facility
6. Novo Nordisk Inc. Announces Exclusive Agreement With Upsher-Smith Laboratories, Inc. to Market Vagifem® 10 mcg
7. Novo Nordisk Addresses Innovation in Diabetes Care in Second Issue of Industry Resource for Information on Diabetes and Chronic Disease
8. Novo Nordisk Announces Resources to Help Support Kids with Diabetes Attending Summer Camp
9. Novo Nordisk Awards More Than $300,000 in Grants to Support Education and Community Health Programs
10. Novo Nordisk partners with international scientific community for Victoza(R) cardiovascular outcomes trial
11. Novo Nordisk Awarded Department of Veterans Affairs National Insulin Contract
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... June 23, 2016 Bracket , a leading ... next generation clinical outcomes platform, Bracket eCOA (SM) 6.0, ... June 26 – 30, 2016 in Philadelphia ... Clinical Outcome Assessment product of its kind to fully integrate ... Bracket eCOA 6.0 is a flexible platform for electronic ...
(Date:6/23/2016)... 2016  Guerbet announced today that it has been ... Award . One of 12 suppliers to ... its support of Premier members through exceptional local customer ... commitment to lower costs. ... our outstanding customer service from Premier," says Massimo ...
(Date:6/23/2016)... June 23, 2016  The National Pharmaceutical Council ... the health policy research organization as its newest ... MD, senior vice president and chief scientific officer, ... on the NPC Board of Directors. ... Mallinckrodt has joined us in support of our ...
Breaking Medicine Technology:
(Date:6/23/2016)... ... June 23, 2016 , ... Virginia Beach resident Sean Kelly ... turned towards the water to find peace and set out to accomplish a personal ... and turned to the internet. He came across the story of another special operations ...
(Date:6/23/2016)... ... 2016 , ... The annual Blue Ribbon Highlights Session took ... and Movement Disorders. This special session provides a critical review of the best ... of both clinical and basic research presented by delegates. , Of the ...
(Date:6/23/2016)... ... 2016 , ... The U.S. Supreme Court decision on immigration has significant consequences ... Senior Citizens League (TSCL) . “President Obama’s executive actions on immigration would have ... worked in this country illegally, even though the newly - issued green cards are ...
(Date:6/23/2016)... ... 23, 2016 , ... For the second time this year, ... Medical Education program, this time in pediatrics. The news from the Accreditation Council ... training that will begin in July 2017. ACGME had previously accredited Memorial’s Physical ...
(Date:6/23/2016)... Research Triangle Park, NC (PRWEB) , ... June 23, 2016 , ... ... Alzheimer’s disease, is announcing that the U.S. Food and Drug Administration (FDA) has granted ... T3D-959 in a limited number of subjects who completed the main Phase 2a study ...
Breaking Medicine News(10 mins):